CD69 and synovial sarcoma: We selected MSGB samples from 9 SS with HT patients, 9 SS without HT patients, and 6 non-SS patients to verify the expression level of the PTPRC, LCP2, CD69, and IKZF1 by H&E and immunohistochemistry.